Arcus makes a narrow bet on casdatifan
- Arcus has no product revenue, so the stock depends on trial data, partners, and cash discipline.
- The company has narrowed around casdatifan, its HIF-2α drug for clear cell kidney cancer.
- The anti-TIGIT program failed in two Phase 3 trials and has been discontinued.
- New clinical partnerships with BMS, Summit, and AVEO will test casdatifan in combinations.
- Gilead is no longer extending broad option rights to Arcus's early-stage pipeline.
One main shot left
Arcus has moved past the shock of its anti-TIGIT failure and picked a new center of gravity. That center is casdatifan, a HIF-2α inhibitor meant to block a cancer survival pathway in clear cell renal cell carcinoma, the most common type of kidney cancer.
The bull case is clear but narrow. Arcus wants casdatifan to beat or outlast Merck's belzutifan and become a backbone drug across kidney cancer treatment lines. Management views Merck's recent LITESPARK-012 failure as an opening to test a front-line triplet of casdatifan, ipi, and an anti-PD-1 drug, projecting a peak sales opportunity of $5 billion to $10 billion.
The bear case highlights the extreme risk of concentrating the company around one drug. By 2027, management expects more than 80% of portfolio spend to go to casdatifan development. That focus can create value if the trials work, but it leaves little room for another late-stage miss.
Finn's score reflects this setup. Performance gets credit for a funded plan and a clear trial calendar. Valuation and the overall score stay low because the company still burns cash, has no approved product, and carries high binary trial risk.
Partner money, not drug sales
Arcus is not selling medicine today. In the first quarter of 2026, it reported $17 million of revenue, all from collaboration categories. The two reported revenue lines were $12 million of license and development services revenue and $5 million of other collaboration revenue.
The old model leaned heavily on Gilead. That model weakened because Gilead chose not to continue its broad option rights to Arcus's early-stage pipeline. Those rights ended in July 2026, removing a key source of outside validation and possible future funding.
To stretch capital, Arcus is signing new clinical collaborations with BMS, Summit, and AVEO. These deals let Arcus retain full rights to casdatifan while sharing the cost of testing it with other drugs. Management also reduced headcount by about 10% to lower the ongoing cost structure.
The business model breaks if partners step back faster than costs fall, or if casdatifan data fail before the newer immune disease pipeline can show useful proof of concept.
Casdatifan at the center
Casdatifan
Casdatifan is the main value driver. It is in the Phase 3 PEAK-1 study for second-line clear cell kidney cancer and is launching into front-line combinations like PEAK-20.
Quemliclustat
Quemliclustat is a CD73 inhibitor in the fully enrolled Phase 3 PRISM-1 trial for pancreatic cancer. A readout in the first half of 2027 could add a second late-stage chance.
AB102
AB102 is an oral MRGPRX2 antagonist for urticaria, a skin disease that causes hives. Arcus expects it to enter Phase 1 in Q3 2026.
Oral TNF inhibitor
This is part of the new inflammation and immunology push. Arcus expects the program to enter the clinic in 2027.
CCR6 antagonist
This is another oral immune disease candidate meant to diversify the company beyond cancer. It is expected to enter the clinic in 2027.
Reported revenue lines
Arcus operates as one reportable segment. For the three months ended March 31, 2026, the mix below uses its two reported revenue categories, both tied to collaborations.
What can break the thesis
Casdatifan trial failure
High impact · Medium oddsArcus is making casdatifan the main company bet. If PEAK-1 misses, or if front-line combination data look weak, the stock could lose its main growth story. Management expects more than 80% of portfolio spend by 2027 to go toward this drug.
Front-line triplet safety
High impact · Medium oddsArcus wants to test casdatifan with ipi and an anti-PD-1 drug in front-line kidney cancer. Three-drug cancer regimens can add severe side effects. A separate AstraZeneca sponsored casdatifan combination study previously paused recruitment because of possible immune-related adverse events.
Partner pullback
Medium impact · High oddsGilead chose not to keep broad option rights to Arcus's early-stage pipeline. That reduces future partner funding potential and weakens outside validation. Taiho still supports casdatifan in certain Asian territories, but the broad Gilead halo is smaller.
BIOSECURE supply chain risk
Medium impact · Medium oddsArcus has disclosed risk from U.S. actions that restrict work with Chinese biotech suppliers. WuXi Biologics in China has been a named manufacturing dependency for some Arcus assets. Supply disruption could slow trials or raise costs.
Cash burn before proof
Medium impact · Medium oddsArcus had a strong cash balance early in 2026, but it also burns significant capital every quarter. The runway is meaningful, yet biotech trials are expensive and failures force resets. New equity could dilute shareholders.
In one breath
Does Arcus Biosciences have approved drugs?
No. Arcus is still clinical stage, which means its drugs are being tested and are not yet approved for sale. Its reported revenue comes from collaborations, not product sales.
What is casdatifan?
Casdatifan is Arcus's HIF-2α inhibitor for clear cell renal cell carcinoma, a common form of kidney cancer. It is now the company's lead asset and the center of its strategy.
Why did the Arcus thesis change in 2026?
The anti-TIGIT program was discontinued after Phase 3 failures, and Gilead decided not to extend broad option rights. Arcus refocused around casdatifan and a newer immune disease pipeline.
What are the next key Arcus catalysts?
The next key items are PEAK-1 enrollment completion in Q4 2026, fall 2026 safety data for the casdatifan triplet, and the initiation of the PEAK-20 frontline Phase 3 trial by year-end 2026.
